Wang Yisi, Chen Yali, Wang Mengyao, Qin Zhaojuan, Zhang Lingli, Zheng Ai, Han Ling
Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China.
Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, Sichuan, China.
Front Oncol. 2023 Sep 19;13:1251453. doi: 10.3389/fonc.2023.1251453. eCollection 2023.
This study aims to preliminarily assess the oncological and reproductive outcomes of fertility preservation treatment using conization combined with pelvic node evaluation in young patients with early-stage cervical cancer (ECC) through meta-analysis.
In this meta-analysis, we analyzed studies published in PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), International Clinical Trials Registry Platform (ICTRP), and Clinical Trials. gov that appeared in our search from inception to 0 7/02/2023.
There were 17 relevant studies with a total of 620 patients included, of which 444 patients received conization combined with pelvic node evaluation. The combined pregnancy rate was 45.4% (95% CI: 0.34-0.57), the combined live birth rate was 33.9% (95% CI: 0.26-0.42), the combined miscarriage rate was 4.8% (95% CI: 0.02-0.092), the combined preterm delivery rate was 5.1% (95% CI: 0.02-0.092), and the combined recurrence rate was 1.9% (95% CI: 0.006-0.035), which did not significantly differ from that of patients who received radical surgery (OR: 0.689, 95% CI: 0.506-0.938).
Cervical conization combined with pelvic lymph node evaluation for fertility preservation in young ECC patients can achieve oncological outcomes similar to radical surgery while improving pregnancy success rates and preserving postoperative fertility. In summary, fertility preservation treatment using cervical conization combined with pelvic lymph node evaluation may be considered as a viable option for young ECC patients with strong fertility preservation desire, resulting in better pregnancy and live birth outcomes.
https://www.crd.york.ac.uk/PROSPERO/#myprospero, identifier PROSPERO (CRD42023423432).
本研究旨在通过荟萃分析初步评估早期宫颈癌(ECC)年轻患者采用宫颈锥切术联合盆腔淋巴结评估进行生育力保留治疗的肿瘤学和生殖结局。
在这项荟萃分析中,我们分析了从创刊至2023年2月7日在PubMed、Embase、Cochrane对照试验中心注册库(CENTRAL)、国际临床试验注册平台(ICTRP)和ClinicalTrials.gov上发表的研究。
共有17项相关研究,纳入患者620例,其中444例患者接受了宫颈锥切术联合盆腔淋巴结评估。综合妊娠率为45.4%(95%CI:0.34 - 0.57),综合活产率为33.9%(95%CI:0.26 - 0.42),综合流产率为4.8%(95%CI:0.02 - 0.092),综合早产率为5.1%(95%CI:0.02 - 0.092),综合复发率为1.9%(95%CI:0.006 - 0.035),与接受根治性手术的患者相比无显著差异(OR:0.689,95%CI:0.506 - 0.938)。
对于年轻的ECC患者,宫颈锥切术联合盆腔淋巴结评估用于生育力保留可获得与根治性手术相似的肿瘤学结局,同时提高妊娠成功率并保留术后生育能力。总之,对于有强烈生育力保留意愿的年轻ECC患者,采用宫颈锥切术联合盆腔淋巴结评估的生育力保留治疗可被视为一种可行的选择,能带来更好的妊娠和活产结局。
https://www.crd.york.ac.uk/PROSPERO/#myprospero,标识符PROSPERO(CRD42023423432)